Filament Health, a clinical-stage natural psychedelic drug development company, has announced a significant expansion of its intellectual property portfolio. The company has received acceptance for 12 patents in Australia, five patents in Canada, and three patents in the US.
The new patents cover processes related to the development of botanical psychedelic drugs, including methods of extraction, purification, standardization, and delivery of naturallyvderived psychedelic drug candidates. Filament's global IP portfolio now contains 46 allowed patents from Canada, the US, Australia, and Mexico.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.